Blood's 70th Anniversary: Arsenic--from Poison Pill to Magic Bullet

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2016 Apr 9

PMID 27056988

Citations 2

Authors

James D Griffin

Affiliations

Soon will be listed here.

Citing Articles

ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia.

Tong Q, You H, Chen X, Wang K, Sun W, Pei Y Nucleic Acids Res. 2018; 46(7):3284-3297.

PMID: 29554366 PMC: 6283422. DOI: 10.1093/nar/gky202.

Influences of Realgar-, A Traditional Chinese Medicine Formula, on the Main CYP450 Activities in Rats Using a Cocktail Method.

Xu H, Hao F, Wang M, Ren S, Li M, Tan H Evid Based Complement Alternat Med. 2017; 2017:2374624.

PMID: 28421119 PMC: 5379094. DOI: 10.1155/2017/2374624.

References

Soignet S, Maslak P, Wang Z, Jhanwar S, Calleja E, Dardashti L . Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998; 339(19):1341-8. DOI: 10.1056/NEJM199811053391901. View

Shen Z, Chen G, Ni J, Li X, Xiong S, Qiu Q . Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89(9):3354-60. View

Rao Y, Li R, Zhang D . A drug from poison: how the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. Sci China Life Sci. 2013; 56(6):495-502. DOI: 10.1007/s11427-013-4487-z. View

Wang Z, Chen Z . Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008; 111(5):2505-15. DOI: 10.1182/blood-2007-07-102798. View

BREITMAN T, Selonick S, Collins S . Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci U S A. 1980; 77(5):2936-40. PMC: 349521. DOI: 10.1073/pnas.77.5.2936. View

Chen G, Shi X, Tang W, Xiong S, Zhu J, Cai X . Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997; 89(9):3345-53. View

Jolliffe D . A history of the use of arsenicals in man. J R Soc Med. 1993; 86(5):287-9. PMC: 1294007. DOI: 10.1177/014107689308600515. View

Coombs C, Tavakkoli M, Tallman M . Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J. 2015; 5:e304. PMC: 4450325. DOI: 10.1038/bcj.2015.25. View

. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-572. Blood. 2016; 128(26):3017. DOI: 10.1182/blood-2016-11-750182. View

10.

Chen S, Zhou G, Zhang X, Mao J, de The H, Chen Z . From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood. 2011; 117(24):6425-37. PMC: 3123014. DOI: 10.1182/blood-2010-11-283598. View

11.

Augusto Dos Santos G, Kats L, Pandolfi P . Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med. 2013; 210(13):2793-802. PMC: 3865469. DOI: 10.1084/jem.20131121. View

12.

Chen G, Zhu J, Shi X, Ni J, Zhong H, Si G . In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996; 88(3):1052-61. View